Monopar Therapeutics Inc (1IY0) Financial Statements
Monopar Therapeutics Inc Financial Overview
Monopar Therapeutics Inc's market cap is currently $421.21M. The company's EPS TTM is $-2.34; its P/E ratio is -30.05; Monopar Therapeutics Inc is scheduled to report earnings on November 6, 2026, and the estimated EPS forecast is $-0.73. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -16.70M | $ -16.16M | $ -8.83M | $ -10.54M | $ -9.13M |
| EBITDA | $ -13.72M | $ -15.59M | $ -8.40M | $ -10.52M | $ -9.10M |
| Net Income | $ -13.72M | $ -15.59M | $ -8.40M | $ -10.52M | $ -9.10M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 140.40M | $ 60.21M | $ 7.27M | $ 13.12M | $ 20.30M |
| Total Assets | $ 140.72M | $ 60.29M | $ 7.35M | $ 13.23M | $ 20.52M |
| Total Debt | $ 154.92K | $ 0.00 | $ 0.00 | $ 8.41K | $ 0.00 |
| Net Debt | $ -61.68M | $ -45.82M | $ -7.27M | $ -8.18M | $ -20.30M |
| Total Liabilities | $ 2.89M | $ 5.25M | $ 1.76M | $ 3.14M | $ 1.58M |
| Stockholders' Equity | $ 137.83M | $ 55.04M | $ 5.59M | $ 10.09M | $ 18.94M |
| Cash Flow | |||||
| Free Cash Flow | $ -12.20M | $ -6.40M | $ -7.86M | $ -7.23M | $ -7.32M |
| Operating Cash Flow | $ -12.20M | $ -6.40M | $ -7.86M | $ -7.23M | $ -7.32M |
| Investing Cash Flow | $ -63.45M | $ -14.34M | $ 4.93M | $ -4.92M | $ 0.00 |
| Financing Cash Flow | $ 91.57M | $ 59.29M | $ 2.03M | $ 32.87K | $ 10.88M |
Currency in USD